Current Report Filing (8-k)
February 08 2022 - 8:30AM
Edgar (US Regulatory)
0001557376
false
0001557376
2022-02-08
2022-02-08
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date
of report (Date of earliest event reported): February 8, 2022
ORGANICELL
REGENERATIVE MEDICINE, INC.
(Exact
name of registrant as specified in its charter)
Nevada
|
|
000-55008
|
|
47-4180540
|
(State or Other Jurisdiction
|
|
(Commission File Number)
|
|
(IRS Employer
|
of Incorporation)
|
|
|
|
Identification No.)
|
4045 Sheridan Avenue, Suite 239, Miami Beach, Florida
|
|
33140
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrant's
telephone number, including area code: (888) 963-7881
_________________________________________________
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each Class
|
|
Trading
Symbol
|
|
Name
of each exchange on which registered
|
None
|
|
N/A
|
|
N/A
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
As
used in this Current Report on Form 8-K, and unless otherwise indicated, the terms “the Registrant,” “the
Company,” “Organicell,” “we,” “us” and “our” refer
to Organicell Regenerative Medicine, Inc. and its subsidiaries.
Item 8.01 Other Events.
On
February 8, 2022, Organicell issued a press release in which it announced that its had secured its first site to carry out the Organicell
Phase I/II Multicenter, Randomized, Double Blinded, Placebo Trial to Evaluate the Safety and Potential Efficacy of Zofin™ Infused
Intravenous (IV) in Patients Experiencing Prolonged COVID-19 Symptoms (Long-Haulers) vs. Placebo.
Item 9.01 Financial Statements and Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Dated: February 8, 2022
|
ORGANICELL REGENERATIVE MEDICINE, INC.
|
|
|
|
By:
|
/s/ Ian Bothwell
|
|
|
Ian
Bothwell
Chief Financial Officer
|